Genaissance Pharmaceuticals, Inc. Invites You to Participate in its First Quarter 2005 Conference Call

Genaissance Pharmaceuticals, Inc. Invites You to Participate in
its First Quarter 2005 Conference Call 


NEW HAVEN, Conn., April 26  /PRNewswire-FirstCall/ -- Genaissance
Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that the Company would
conduct a conference call on Tuesday, May 3, 2005, at 11:00 a.m. Eastern time
(ET), in conjunction with the release of its financial results for the first
quarter ended March 31, 2005.

To participate in this conference call, dial 719-457-2629, confirmation code
4544361, shortly before 11:00 a.m. ET.  A replay of the call will be available
from 2:00 p.m. ET through midnight Monday, May 9, 2005.  The replay number is
719-457-0820, confirmation code 4544361.

Genaissance Pharmaceuticals, Inc. is developing innovative products based on
its proprietary pharmacogenomic technology and has a revenue-generating
business in DNA and pharmacogenomic products and services.  Genaissance also
markets its proprietary FAMILION(TM) Test, designed to detect mutations
responsible for causing Familial Long QT and Brugada Syndromes, two causes of
sudden cardiac death.  The Company's product development strategy is focused on
drug candidates with promising clinical profiles and finding genetic markers to
identify a responsive patient population.  This strategy is designed to enable
Genaissance to leverage existing clinical data and, thus, reduce the costs and
risks associated with traditional drug development and increase the probability
of clinical success and commercialization.  The Company's lead therapeutic
product, vilazodone for depression, is in Phase II of development.  For more
information on Genaissance, visit the company website at:
http://www.genaissance.com/. 

DATASOURCE: Genaissance Pharmaceuticals, Inc.



CONTACT: Rhonda Chiger, [phone],  of Rx

Communications Group, for Genaissance Pharmaceuticals, Inc.



Web site:  http://www.genaissance.com/ 

Copyright